Security for Pharmaceutical and Biotech Executives

Pharmaceutical and biotech executives occupy an unusual position in the corporate security threat landscape. They face threats from multiple directions simultaneously: state-sponsored intelligence services targeting proprietary research, activist groups opposed to animal testing or drug pricing policy, criminal networks in some operating regions, and the standard risks associated with executive profile and travel to high-risk markets.

Few other sectors produce this combination. A technology executive faces primarily the first and last categories. A resources sector executive faces primarily the third and last. The pharmaceutical executive faces all four, sometimes at the same time.

Understanding the threat profile clearly is the starting point for proportionate security planning.

State-Sponsored IP Theft: The Intelligence Dimension

Pharmaceutical intellectual property – clinical trial data, formulation files, manufacturing processes, pipeline compound structures – is among the most actively targeted categories of corporate information by state-sponsored intelligence services.

The FBI, GCHQ, and NCSC have all issued public warnings about state-sponsored targeting of pharmaceutical research. During the COVID-19 period, NCSC and CISA issued a joint advisory in 2020 specifically warning that APT (Advanced Persistent Threat) actors affiliated with state intelligence services were targeting vaccine development organisations. Post-pandemic, the targeting has shifted to oncology pipelines, gene therapy platforms, and rare disease compounds where the commercial value of a data set can represent years of development expenditure.

The FBI has attributed multiple pharmaceutical espionage operations to Chinese state-affiliated actors under operations including APT41 and associated groups. The targeting methodology in documented cases has included both cyber intrusion and HUMINT operations: cultivating insiders, approaching researchers at conferences, and using front companies to conduct business development outreach to pharma principals that provides a pretext for information access.

For pharmaceutical executives, this has direct physical security implications. An executive travelling to China, attending a major conference with Chinese industry participation, or meeting counterparts from state-affiliated pharmaceutical companies should have a device security protocol in place that matches the sensitivity of the information they carry.

Sources: NCSC/CISA joint advisory 2020 on healthcare and research sector targeting; FBI IP theft enforcement actions 2024; GCHQ NCSC 2024 annual review.

Device Security for Conference Travel

Pharmaceutical conferences – JPMorgan Healthcare Conference, ASCO, BIO International, CPhI – concentrate executives carrying commercially sensitive pipeline information in environments that are difficult to secure.

Conference Wi-Fi is, by default, an untrusted network. Corporate devices connected to conference Wi-Fi without VPN protection are exposed to man-in-the-middle attacks and passive traffic interception. This is not a theoretical risk at high-value pharmaceutical conferences; it is a documented practice.

The clean device protocol applies here as it does in any high-risk intelligence environment: the travel device contains only the information required for the specific meetings, with no persistent access to corporate network repositories. Full-disk encryption is a baseline requirement. Specific pipeline data or deal information should be shared only through secure channels, not on a conference slide deck left open on a laptop in a hotel lobby meeting.

Physical meeting room security matters for sensitive discussions. A meeting room in a conference hotel cannot be treated as a secure environment without a TSCM sweep. For discussions involving clinical trial data, licensing terms, or acquisition negotiations, the appropriate venue is a pre-arranged secure room with a controlled access list, not a hotel breakout space.

Social engineering at pharmaceutical conferences is documented. Individuals presenting as research collaborators, potential partners, or investment contacts have been used by state intelligence services to gather information that would not be shared in formal due diligence. The standard counter is the same as in any intelligence environment: be specific about what information you share and with whom, regardless of how legitimate the contact appears.

Activist Targeting: A Different Category of Threat

The activist threat facing pharmaceutical executives primarily comes from animal rights organisations opposed to animal testing in pharmaceutical research. This threat category has a documented operational history in the UK and US that extends to home protests, property damage, and harassment campaigns against named executives.

Animal Liberation Front and related networks have been classified by the FBI as domestic terrorist organisations following a pattern of criminal activity that has included arson, property destruction, and personal harassment. In the UK, organisations including Stop Huntingdon Animal Cruelty (SHAC) operated sustained campaigns against executives of pharmaceutical and contract research companies that included residential protests, personal intimidation, and the publication of home addresses.

The primary protective measures for activist threat are different from those for criminal or state threat. They focus on reducing the information available to activists rather than on physical response capability.

Home address should not appear in company filings, Companies House records, or property registries under the individual’s name. Where it does appear, removal applications through the relevant registry procedures are available in some jurisdictions. The Electoral Register opt-out (anonymised registration) is available in the UK for individuals with a safety concern.

Residential security measures appropriate for activist threat include perimeter lighting, quality CCTV with off-site recording, good neighbour awareness, and a clear contact protocol with local police. Unlike criminal threat mitigation, overt security measures at the residence can serve a deterrence function for activist groups: the marginal cost of targeting a well-secured property rather than a less-secured one often displaces the campaign elsewhere.

Clinical Trial Sites in High-Risk Countries

Pharmaceutical and biotech companies operating clinical trials in high-risk countries create predictable populations of foreign medical and research personnel. Site staff follow documented routines: hospital and clinic visits, site monitoring rotations, and regular air travel to and from the trial site. This predictability creates a targeting profile.

Site security assessment should be part of the site selection process, not an afterthought. The operating environment assessment should cover ground transport risk, accommodation security standards, kidnap and ransom risk in the specific region, and the political stability of the regulatory environment.

Personnel rotating through high-risk clinical sites should receive HEAT training before deployment and be covered by medical evacuation and K&R insurance. ISO 31030:2021 Travel Risk Management applies to these deployments as clearly as it does to any corporate business travel. The duty of care obligation is identical whether the employee is an executive attending a board meeting or a clinical research associate conducting site monitoring visits.

In regions where kidnap for ransom is a documented risk – parts of sub-Saharan Africa, certain Latin American jurisdictions, some areas of South and Southeast Asia – site rotation schedules should vary arrival and departure timing where possible, and ground transport from airports to sites should be vetted and pre-arranged rather than managed ad hoc.

Sources: OSAC Healthcare Sector 2024; Control Risks RiskMap 2025; ISO 31030:2021.

Product Launch and Market Entry Travel

Major pharmaceutical product launches involve an intensive travel period: regulatory submissions in multiple jurisdictions, investor and analyst presentations, market access meetings, and media events. This creates a period of unusually high predictability for executives who are normally able to vary their routines.

During a product launch period, the principal’s travel schedule may be known to multiple external parties – investor relations teams, regulatory counterparts, media contacts – weeks in advance. The standard route variation and schedule compartmentalisation disciplines are harder to apply when the schedule is being actively communicated to maximise media coverage.

Security planning for a product launch period should account for this predictability increase. Advance work for the key appearances, vetted ground transport for the full period, and briefing the CP team on the elevated schedule exposure are appropriate responses.

For executives attending launch events in markets where political risk, activist targeting, or organised crime risk is elevated, the security posture should be specifically reviewed for the launch period rather than defaulted to standard business travel arrangements.

Integrating the Threat Picture

Pharmaceutical executives who approach their security planning as though all threats are equivalent will apply incorrect controls across the board. The activist threat requires a different response from the state espionage threat, which requires a different response from the criminal targeting risk.

A credible pharmaceutical sector security programme separates these threat categories, assesses each against the specific principal’s profile and operating environment, and applies proportionate controls to each. The programme is reviewed when the threat picture changes: a new product announcement that creates activist attention, a market entry into a new jurisdiction, a change in geopolitical conditions affecting partner countries.

For the device security and digital protection measures that address the IP theft dimension, see our executive digital security guide. For protecting commercially sensitive information during international travel and at conferences, see our protecting trade secrets guide. For HEAT training applicable to clinical site personnel in high-risk regions, see our HEAT training guide. For the full corporate travel security policy framework, see our corporate travel security policy guide. For the broader healthcare and life sciences security environment – including state-sponsored IP theft targeting clinical data, fixated patient and activist threats, and ISO 31030 duty of care for clinical site personnel – see our security for healthcare executives guide. For the supply chain and asset protection dimension – drug theft, cold chain security, counterfeit medicine infiltration, and clinical trial material transit in high-risk markets – see our pharmaceutical supply chain security guide. For the physical security of pharmaceutical research laboratories and R&D facilities – including FDA 21 CFR Part 211 compliance, insider threat in laboratory environments, cleanroom access control design, and IP theft via the trusted insider pattern documented in FBI Economic Espionage Act prosecutions – see our pharmaceutical laboratory and R&D security guide. For the personal security of executives and researchers facing targeted animal rights campaigns – including the SHAC secondary targeting model, SOCA 2005 provisions, home address suppression from electoral registers, and residential security review as a duty of care obligation – see our security for corporate targets of animal rights extremism guide. For the IP theft and physical security dimensions specific to genetic and genomic research – BGI and PRC state genomic data collection, FBI biotech IP theft case law, GDPR Article 9 obligations for genomic data, and laboratory access control – see our genetic and biotech IP protection guide. For the cold chain and cargo security framework that pharmaceutical supply chains require – TAPA FSR/TSR standards, the Eli Lilly USD 75 million warehouse theft case, FSMA intentional adulteration rules, serialisation under FMD and DSCSA, and P1 city distribution vulnerabilities – see our pharmaceutical cold chain and logistics security guide.